Skip to main content
ORMP
NASDAQ Life Sciences

Oramed Q3 2026: $134.9M Net Income on Alpha Tau Markup; Cash Falls to $28.9M

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$4.03
Mkt Cap
$167.637M
52W Low
$2.25
52W High
$5.47
52W Position info
79% above low
Off High info
26% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

ORMP sits 79% above its 52-week low of $2.25.

Summary

Oramed posted $134.9M of nine-month net income driven by a $174.5M non-cash Alpha Tau revaluation gain, while cash fell to $28.9M and it added a new $9.0M mortgage guaranty.


Key Events · Earnings and Guidance · ORMP

  • Paper Profit From Alpha Tau Markup

    Nine-month net income of $134.9M was driven by a $174.5M unrealized gain on the Alpha Tau stake, now worth $252.4M — about 63% of total assets.

  • Cash Falls to $28.9M

    Cash and equivalents dropped from $45.9M at Dec 31, 2025 to $28.9M, after a $10.5M dividend and $11.9M deployed into the Lifeward transaction.

  • Deferred Tax Liability Jumps

    Deferred tax liabilities rose to $50.1M from $7.9M, mainly tied to unrealized gains on the Alpha Tau investment.

  • New $9.0M Mortgage Guaranty

    On Nov 6, 2026 Oramed joined a joint-and-several guaranty of a $9.0M Fieldpoint mortgage to MAR Bailey Avenue LLC, stepping down to 25% once a debt service coverage ratio is met.


Analysis · ORMP · Life Sciences

The headline profit is almost entirely paper: $174.5M of the $180.5M financial income came from marking up the Alpha Tau stake, which now sits at $252.4M — roughly 63% of total assets. That concentration is the real story. Cash dropped to $28.9M from $45.9M at year-end after a $10.5M dividend and $11.9M into the Lifeward deal, and deferred tax liabilities ballooned to $50.1M from $7.9M on those unrealized gains. In November the company also signed a new $9.0M joint-and-several guaranty on a Buffalo self-storage mortgage, adding off-balance-sheet exposure. With no revenue-generating operations after transferring the POD platform, Oramed is now effectively a leveraged bet on Alpha Tau's share price.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ORMP was trading at $4.03 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $167.6M. The 52-week trading range was $2.25 to $5.47. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ORMP - Latest Insights

ORMP
Aug 10, 2026, 5:29 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $4.20
Real-time Price: $4.03 info
Change: -$0.170 (-4%) info
Market Cap: $167.637M info
ORMP
Jun 30, 2026, 4:19 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.81
Real-time Price: $4.03 info
Change: -$0.780 (-16%) info
Market Cap: $167.637M info
ORMP
May 19, 2026, 5:08 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $4.33
Real-time Price: $4.03 info
Change: -$0.300 (-7%) info
Market Cap: $167.637M info
ORMP
Mar 31, 2026, 4:20 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.40
Real-time Price: $4.03 info
Change: +$0.630 (+19%) info
Market Cap: $167.637M info
ORMP
Mar 26, 2026, 5:25 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $3.32
Real-time Price: $4.03 info
Change: +$0.710 (+21%) info
Market Cap: $167.637M info